Abstracts - faqs.org

Abstracts

Business, international

Search abstracts:
Abstracts » Business, international

Roche unit in pact to develop tools for gene research

Article Abstract:

Roche Diagnostics has signed a deal with CombiMatrix Corp. for developing genetics research and diagnostic tools. The terms of the contract call for Roche to market the microarrays and the companies to develop new research and testing tools.

Author: Anand, Geeta
Publisher: Dow Jones Publishing Co. (Europe)
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 2001
Germany, Research and Development in the Physical, Engineering, and Life Sciences, Alliances, partnerships, Commercial physical research, Research & Development-Industry, Industrial research, Contracts, Roche Diagnostics GmbH, CombiMatrix Corp.

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Small firms may play big role in U.S. stockpile of vaccines; Therion, Novavax ready to respond to threat of smallpox outbreak

Article Abstract:

Merck & Co., American Home Products, and Glaxo-SmithKline are the large pharmaceutical firms expected to lead in the race to ready the stockpile of smallpox vaccine the U.S. wants on hand, but two small firms could help out in the meantime. Therion Biologics says it could make 2 million doses in 2 weeks. Novavax says it could make 16 million doses every other week.

Author: Anand, Geeta
Publisher: Dow Jones Publishing Co. (Europe)
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 2001
Product information, Pharmaceutical Preparation Manufacturing, Pharmaceutical Preparations, Biological products exc. diagnostic, Vaccines for Human Use, Drugs, Prevention, Influence, Vaccines industry, Biological products industry, Vaccines, Bioterrorism, Smallpox, Therion Biologics Corp., Novavax Inc., NOX

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Wary of backlash, cancer-drug makers weigh price limits

Article Abstract:

High prices for cancer drugs are causing an outcry so biotechnology and pharmaceutical companies are considering price caps and ways to decrease costs. Two of the cancer drugs being considered for price caps are Erbitux and Avastin.

Author: Carreyrou, John, Anand, Geeta
Publisher: Dow Jones Publishing Co. (Europe)
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 2006
Financial management, Commodity & service prices, Public affairs, Finance, Prices and rates, Cancer, Public relations, Chemotherapy, Company public relations, Company financing, Company pricing policy, Industry overview

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: United States, Pharmaceutical industry
Similar abstracts:
  • Abstracts: Some Asian airlines appear ready for Y2K: analysts are most confident about the preparedness of major carriers
  • Abstracts: Bajaj Auto's new models may jump-start its stock price; Indian motorcycle maker aims to recoup lost ground; investors await more evidence of success
  • Abstracts: GDF urges a resolution of merger deal with Suez: France vows decision by end of September; profit decline posted
  • Abstracts: Microsoft faces EU fines, imposition of sales rules: failure to reach an accord in Windows antitrust case poses huge possible hurdle
  • Abstracts: DBS Group announces purchase of Dao Heng to skeptical investors. EU agrees to let Hutchison, partners take control of port
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.